Letter to the Editor: Optimizing platelet-rich plasma therapy for diabetic foot ulcers: From bench to bedside

doi:10.4239/wjd.116113

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

(1)

(2)

(0)

(6)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Correspondence

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Jul 15, 2026; 17(7): 116113
Published online Jul 15, 2026. doi: 10.4239/wjd.116113

Letter to the Editor: Optimizing platelet-rich plasma therapy for diabetic foot ulcers: From bench to bedside

Wu Wei, Li-Rong Huang, Cong Wang, Zeng-Hui Lu

Wu Wei, Li-Rong Huang, Cong Wang, Zeng-Hui Lu, Department of Vascular Surgery, Jiangxi Province Hospital of Integrated Chinese and Western Medicine, Nanchang 330003, Jiangxi Province, China

Author contributions: Wei W and Lu ZH designed the study; Wang C analyzed the data; Wei W and Huang LR wrote the manuscript with input from all authors.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Corresponding author: Zeng-Hui Lu, Department of Vascular Surgery, Jiangxi Province Hospital of Integrated Chinese and Western Medicine, No. 90 Bayi Road, Xihu District, Nanchang 330003, Jiangxi Province, China. 1125488944@qq.com

Received: November 2, 2025
Revised: December 29, 2025
Accepted: January 16, 2026
Published online: July 15, 2026
Processing time: 248 Days and 19.3 Hours

Core Tip

Core Tip: This commentary builds upon a recent study to propose key refinements for platelet-rich plasma (PRP) therapy in diabetic foot ulcers. We argue against a uniform PRP concentration, advocating instead for cell-type-specific formulations. Furthermore, we highlight the need to address diabetic endothelial dysfunction beyond angiogenesis, and to establish standardized, clinically-relevant protocols based on PRP bioactivity and precise patient stratification. These steps are crucial to transition PRP from a promising treatment to a reliably optimized and personalized therapeutic strategy.